Traws Pharma Announces Management Updates
Traws Pharma (NASDAQ: TRAW) announced key management changes as CEO Werner Cautreels, PhD, will retire effective March 31, 2025, following the company's Annual Report filing. Executive Board Chairman Iain D. Dukes, D Phil, will step in as Interim CEO while maintaining his Chairman position.
Dr. Cautreels will remain on the Board of Directors and transition to a consulting role as special advisor for the next year. Under his leadership, the company completed the merger with Trawsfynydd to form Traws Pharma, advancing two clinical-stage antiviral candidates for bird flu and COVID.
The company will hold an Investor Update call on March 31, 2025, at 10:00 AM ET to review pipeline progress. Traws Pharma focuses on developing novel therapies targeting respiratory viral diseases through oral small molecule antivirals.
Traws Pharma (NASDAQ: TRAW) ha annunciato importanti cambiamenti nella gestione, poiché il CEO Werner Cautreels, PhD, si ritirerà a partire dal 31 marzo 2025, dopo la presentazione del rapporto annuale dell'azienda. Il presidente del Consiglio Esecutivo Iain D. Dukes, D Phil, assumerà il ruolo di CEO ad interim mantenendo la sua posizione di presidente.
Il Dr. Cautreels rimarrà nel Consiglio di Amministrazione e passerà a un ruolo di consulenza come consigliere speciale per il prossimo anno. Sotto la sua guida, l'azienda ha completato la fusione con Trawsfynydd per formare Traws Pharma, portando avanti due candidati antivirali in fase clinica per l'influenza aviaria e il COVID.
L'azienda terrà una chiamata di aggiornamento per gli investitori il 31 marzo 2025, alle 10:00 AM ET, per esaminare i progressi del pipeline. Traws Pharma si concentra sullo sviluppo di terapie innovative mirate alle malattie virali respiratorie attraverso antivirali a piccole molecole orali.
Traws Pharma (NASDAQ: TRAW) anunció cambios clave en la gestión, ya que el CEO Werner Cautreels, PhD, se retirará a partir del 31 de marzo de 2025, tras la presentación del informe anual de la empresa. El presidente de la Junta Ejecutiva Iain D. Dukes, D Phil, asumirá el cargo de CEO interino mientras mantiene su posición como presidente.
El Dr. Cautreels permanecerá en la Junta Directiva y pasará a un rol de consultoría como asesor especial durante el próximo año. Bajo su liderazgo, la empresa completó la fusión con Trawsfynydd para formar Traws Pharma, avanzando dos candidatos antivirales en etapa clínica para la gripe aviar y el COVID.
La empresa llevará a cabo una llamada de actualización para inversores el 31 de marzo de 2025, a las 10:00 AM ET, para revisar el progreso del pipeline. Traws Pharma se centra en desarrollar terapias novedosas que apunten a enfermedades virales respiratorias a través de antivirales orales de pequeñas moléculas.
트로스 제약 (NASDAQ: TRAW)은 CEO 베르너 카우트릴스 박사가 2025년 3월 31일부로 은퇴한다고 발표했습니다. 이는 회사의 연례 보고서 제출 이후에 이루어지는 일입니다. 이사회 의장 아이언 D. 듀크스, D Phil는 의장직을 유지하면서 임시 CEO로 임명될 것입니다.
카우트릴스 박사는 이사회에 남아 다음 해 동안 특별 자문 역할로 전환할 것입니다. 그의 지도 아래, 회사는 트로스피니드와의 합병을 완료하여 트로스 제약을 형성하고, 조류 독감 및 COVID에 대한 두 가지 임상 단계 항바이러스 후보를 발전시켰습니다.
회사는 2025년 3월 31일 오전 10시(동부 표준시)에 투자자 업데이트 전화를 개최하여 파이프라인 진행 상황을 검토할 것입니다. 트로스 제약은 경구용 소분자 항바이러스를 통해 호흡기 바이러스 질환을 타겟으로 하는 혁신적인 치료법 개발에 집중하고 있습니다.
Traws Pharma (NASDAQ: TRAW) a annoncé des changements clés dans la direction, le PDG Werner Cautreels, PhD, prenant sa retraite à compter du 31 mars 2025, après le dépôt du rapport annuel de l'entreprise. Le président du conseil d'administration Iain D. Dukes, D Phil, assumera le rôle de PDG par intérim tout en conservant sa position de président.
Le Dr Cautreels restera au conseil d'administration et passera à un rôle de consultant en tant que conseiller spécial pour l'année à venir. Sous sa direction, l'entreprise a finalisé la fusion avec Trawsfynydd pour former Traws Pharma, faisant progresser deux candidats antiviraux en phase clinique pour la grippe aviaire et le COVID.
L'entreprise tiendra un appel de mise à jour pour les investisseurs le 31 mars 2025, à 10h00 ET, pour examiner les progrès du pipeline. Traws Pharma se concentre sur le développement de thérapies novatrices ciblant les maladies virales respiratoires à travers des antiviraux oraux à petites molécules.
Traws Pharma (NASDAQ: TRAW) gab wichtige Änderungen im Management bekannt, da CEO Werner Cautreels, PhD, zum 31. März 2025 zurücktritt, nach der Einreichung des Jahresberichts des Unternehmens. Der Vorsitzende des Vorstands Iain D. Dukes, D Phil, wird als Interims-CEO einspringen und gleichzeitig seine Position als Vorsitzender beibehalten.
Dr. Cautreels wird im Vorstand bleiben und im nächsten Jahr eine beratende Rolle als Sonderberater übernehmen. Unter seiner Leitung hat das Unternehmen die Fusion mit Trawsfynydd abgeschlossen, um Traws Pharma zu gründen und zwei antivirale Kandidaten in klinischer Phase gegen Vogelgrippe und COVID voranzutreiben.
Das Unternehmen wird am 31. März 2025 um 10:00 Uhr ET eine Investoren-Update-Konferenz abhalten, um den Fortschritt des Portfolios zu überprüfen. Traws Pharma konzentriert sich auf die Entwicklung neuartiger Therapien, die auf respiratorische Viruskrankheiten durch orale kleine Molekülantiviren abzielen.
- Smooth leadership transition with former CEO remaining involved as Board member and special advisor
- New Interim CEO brings extensive experience in corporate, strategic and product development
- Company maintains continuity in development of two clinical-stage antiviral candidates
- CEO departure could create temporary organizational uncertainty
- Interim nature of new CEO appointment suggests potential ongoing leadership instability
- Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member
- Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO
NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assume the role of Interim CEO. In addition to his new responsibilities, Dr. Dukes will continue to serve as Traws’ Chairman.
Dr. Dukes has held leadership roles in public and private biopharmaceutical companies, leveraging vast experience in corporate, strategic and product development. Dr. Cautreels will continue in his role as a member of the Traws Board of Directors and transition to a consulting role as special advisor to the Board for the next year.
"On behalf of the Board of Directors, I want to express my sincerest appreciation to Werner for his unwavering commitment and dedicated service. Under his leadership, the Company completed the merger with Trawsfynydd to form Traws Pharma, advancing two exciting clinical-stage antiviral candidates for bird flu and COVID,” said Dr. Dukes of Traws. “I believe that Traws’ novel antiviral programs have the potential to substantially improve the care of people with influenza and COVID. We look forward to reviewing the Company’s pipeline progress in our Investor Update call on March 31, 2025.”
“I am grateful to the employees, advisors, investors and collaborators who have supported Traws’ development and progress since the merger, just one year ago. It has been a privilege to work with such an impressive management team, and advance our bird flu and COVID programs, while garnering the support of important institutional investors,” commented Dr. Cautreels. “I look forward to continuing to support Traws in my new role, as the Company takes the next steps in the development of its portfolio of oral small molecule antivirals.”
Register here for the Investor Call on Monday, March 31, 2025 at 10:00 AM ET.
About Iain D. Dukes, D Phil
Dr. Dukes is biopharmaceutical professional with substantial experience in senior leadership roles in venture capital, business development and licensing, as well as drug discovery and development. He is a Venture Partner of OrbiMed Advisors, LLC. Previously, Dr. Dukes served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories. Before joining Merck, Dr. Dukes held senior leadership roles in Business Development and Research and Development at Amgen, GlaxoSmithkline, and Glaxo Wellcome.
Dr. Dukes has served on the board of numerous public and private biopharma organizations. He is currently the Chairman of the board of directors of Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) and Executive Chairman of Angiex Inc. He also serves as a director or founding executive on other public and private boards including Ikena Oncology (Nasdaq: IKNA), ENYO Pharma SA, Kartos Therapeutics, Inc., NeRRe Therapeutics, Rathlin Therapeutics Limited, and Telios Pharma, Inc. Dr. Dukes holds an MA in Jurisprudence and D Phil from the University of Oxford, an MSc in Cardiovascular Studies from the University of Leeds, and a BSc in Pharmacology from the University of Bath.
About Werner Cautreels
Dr. Werner Cautreels is a highly accomplished biopharmaceutical executive who brings a deep understanding of research and development, as well as clinical and regulatory strategy, across a range of therapeutic areas. Dr. Cautreels was previously President and CEO of Selecta Biosciences. Prior to Selecta Biosciences, Dr. Cautreels held senior leadership roles at international biopharmaceutical organizations around the world including Solvay Pharmaceuticals (as CEO, acquired by Abbott Laboratories), Sanofi, Sterling Winthrop and Nycomed-Amersham.
Dr. Cautreels has served as a member of the audit committee and board for biopharmaceutical companies including Innogenetics NV, Arqule Inc., and Galapagos NV. Dr. Cautreels currently serves on the board of directors of Third Pole Therapeutics. Dr. Cautreels also serves as CEO of Cristal Therapeutics and Non-Executive Chairman of MRM Health NV. Dr. Cautreels has a PhD in chemistry from the University of Antwerp, Belgium, and completed the Advanced Management Program at Harvard Business School.
About Traws Pharma, Inc.
Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health. Our product candidates are intended to be safe, with simple dosing regimens. We strive to utilize accelerated clinical trial strategies with a commitment to patients who are especially vulnerable.
The Company’s two antiviral programs are investigational oral small molecules targeting bird flu and seasonal influenza, and COVID-19. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a COVID treatment, targeting the Main protease (Mpro or 3CL protease), without the need for co-administration of ritonavir.
For more information, please visit www.trawspharma.com and follow us on LinkedIn.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, benefits, effectiveness, safety, and the clinical and regulatory plans for tivoxavir marboxil and ratutrelvir and the timing of the filing of the Company’s Annual Report on Form 10-K. The Company has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Traws’ clinical trials, collaborations, market conditions, regulatory requirements and pathways for approval, the extent of the spread and threat of the bird flu, the ongoing need for improved therapy to reduce the frequency of clinical rebound and the concomitant risk for long COVID, and those discussed under the heading “Risk Factors” in Traws’ filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.
Traws Pharma Contact:
Nora Brennan
Traws Pharma, Inc.
nbrennan@trawspharma.com
www.trawspharma.com
Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com
FAQ
When will Werner Cautreels retire as CEO of Traws Pharma (TRAW)?
Who will be the interim CEO of Traws Pharma (TRAW) after Cautreels' retirement?
What are the main clinical programs in development at Traws Pharma (TRAW)?
What role will Werner Cautreels maintain at Traws Pharma (TRAW) after stepping down as CEO?
